The FDA claims that Pathway’s CancerIntercept Detect, which costs $699, counts as a direct-to-consumer test because it ships blood collection tubes, technically considered to be medical devices, ...
On June 10th, the agency sent letters to Illumina, of San Diego, Pathway Genomics also of San Diego, NaviGenics, 23andMe and deCODE Genetics, of Reykjavik, Iceland, explaining that their genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback